DeepMed Research

ADAPTIMMUNE LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2

Active, not recruiting

Conditions: Myxoid Liposarcoma
Synovial Sarcoma

Interventions: Genetic: afamitresgene autoleucel (previously ADP-A2M4)

First Posted Date: 2019-08-05

Last Posted Date: 2025-01-13

Lead Sponsor: Adaptimmune

Target Recruit Count: 52

Registration Number: NCT04044768

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 23 locations

ADP-A2M4CD8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)

Phase 1

Active, not recruiting

Conditions: Melanoma
Gastric (Stomach) Cancer
Esophageal Cancer
Esophagogastric Junction (EGJ)
Head and Neck Cancer
Urothelial Cancer
Endometrial Cancer
Ovarian Cancer
Non-small Cell Lung (NSCLC)

Interventions: Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

First Posted Date: 2019-08-05

Last Posted Date: 2025-03-13

Lead Sponsor: Adaptimmune

Target Recruit Count: 120

Registration Number: NCT04044859

Locations: 🇺🇸
Name of Institution: Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Washington University - School of Medicine, Saint Louis, Missouri, United States

and more 14 locations

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Phase 2

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Letetresgene autoleucel (lete-cel, GSK3377794)
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-05-30

Last Posted Date: 2024-10-11

Lead Sponsor: Adaptimmune

Target Recruit Count: 103

Registration Number: NCT03967223

Locations: 🇪🇸
Hospital Virgen Del Rocio, Sevilla, Spain
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States

and more 34 locations

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Terminated

Conditions: Solid and Hematological Malignancies

Interventions: Genetic: Genetically engineered T Cell Receptors

First Posted Date: 2018-01-05

Last Posted Date: 2021-01-07

Lead Sponsor: Adaptimmune

Target Recruit Count: 2

Registration Number: NCT03391791

Locations: 🇨🇦
Princess Margaret Cancer Centr, Toronto, Ontario, Canada
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Biological: ADP adoptive cell therapy

First Posted Date: 2018-01-05

Last Posted Date: 2024-07-03

Lead Sponsor: Adaptimmune

Target Recruit Count: 250

Registration Number: NCT03391778

Locations: 🇩🇪
Uniklinik Köln, Koeln, Nordrhein-Westfalen, Germany
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 20 locations

MAGE-A4ᶜ¹º³²T for Multi-Tumor

Phase 1

Active, not recruiting

Conditions: Urinary Bladder Cancer
Melanoma
Ovarian Cancer
Esophageal Cancer
Synovial Sarcoma
Gastroesophageal Junction
Non-Small Cell Lung Cancer
Head and Neck Cancer
Gastric Cancer
Myxoid Round Cell Liposarcoma

Interventions: Radiation: Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
Genetic: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells

First Posted Date: 2017-04-28

Last Posted Date: 2024-01-22

Lead Sponsor: Adaptimmune

Target Recruit Count: 71

Registration Number: NCT03132922

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 8 locations

AFPᶜ³³²T in Advanced HCC

Phase 1

Active, not recruiting

Conditions: AFP Expressing Tumors
Hepatocellular Cancer

Interventions: Genetic: Autologous genetically modified AFPᶜ³³²T cells

First Posted Date: 2017-04-28

Last Posted Date: 2024-08-15

Lead Sponsor: Adaptimmune

Target Recruit Count: 45

Registration Number: NCT03132792

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 18 locations

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Phase 1

Completed

Conditions: Melanoma
Urothelial Carcinoma
Head and Neck Cancer
Bladder Urothelial Carcinoma

Interventions: Genetic: Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

First Posted Date: 2016-12-12

Last Posted Date: 2020-12-19

Lead Sponsor: Adaptimmune

Target Recruit Count: 10

Registration Number: NCT02989064

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States

and more 8 locations

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Completed

Conditions: Solid and Hematological Malignancies

First Posted Date: 2015-12-22

Last Posted Date: 2025-03-04

Lead Sponsor: Adaptimmune

Target Recruit Count: 9122

Registration Number: NCT02636855

Locations: 🇪🇸
Hospital 12 De Octubre, Madrid, Spain
🇪🇸
Hospital Universitario 12 Octubre Avda. de Córdoba s/n, Madrid, Spain
🇺🇸
City of Hope, Duarte, California, United States

and more 33 locations

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Phase 1

Completed

Conditions: Carcinoma
Non-Small Cell Lung Cancer

Interventions: Biological: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T

First Posted Date: 2015-10-30

Last Posted Date: 2021-04-09

Lead Sponsor: Adaptimmune

Target Recruit Count: 28

Registration Number: NCT02592577

Locations: 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇬🇧
University College Hospital Macmillan Cancer Centre, London, United Kingdom

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy